Video yükleniyor...

Video Yüklenemedi

Ana Sayfaya Dön

Can bio foundation models solve the most critical therapeutics problem, predicting which patients will respond to a therapy? Today, we share more details in a white paper on our recently reported results using NOETIK TARIO-2 to predict responders in an actual clinical trial setting with Agenus.

Ronalfa's profile picture

Ron Alfa

7,002 subscribers

17,153 görüntüleme • 24 gün önce •via X (Twitter)

LIVE

Anya Rossi• Live Now

Private livecam show

0 Yorum

Yorum bulunmuyor

Orijinal gönderinin yorumları burada görünecek

Benzer Videolar

🔬 Training Transformers to solve 95% failure rate of Cancer Trials the AI for Science pod is back with Ron Alfa, CEO of NOETIK, and Daniel Bear, VP Research at Noetik, explaining exactly how their team of top AI x Bio researchers and engineers (shoutout owl) will use AI to cure cancer, by focusing on key bottlenecks like patient selection, and training large cancer foundation models like TARIO-2, an autoregressive transformer trained on one of the largest sets of tumor spatial transcriptomics datasets in the world... which first required years of blind faith in collecting good data to even get going:
0:55

🔬 Training Transformers to solve 95% failure rate of Cancer Trials the AI for Science pod is back with Ron Alfa, CEO of NOETIK, and Daniel Bear, VP Research at Noetik, explaining exactly how their team of top AI x Bio researchers and engineers (shoutout owl) will use AI to cure cancer, by focusing on key bottlenecks like patient selection, and training large cancer foundation models like TARIO-2, an autoregressive transformer trained on one of the largest sets of tumor spatial transcriptomics datasets in the world... which first required years of blind faith in collecting good data to even get going:

Latent.Space

18,260 görüntüleme • 2 ay önce

Scientists say the first clinical trial to test whether adults - with a severe allergy to peanuts - can safely tolerate them, has had positive results. Ciara ITV has more details.
1:42

Scientists say the first clinical trial to test whether adults - with a severe allergy to peanuts - can safely tolerate them, has had positive results. Ciara ITV has more details.

Good Morning Britain

13,411 görüntüleme • 1 yıl önce

Boris Johnson tells an audience in Taiwan, "We will solve the problem of a shortage of social care workers which we have in the UK" "Not with more immigrants but with ChatGPT"
0:23

Boris Johnson tells an audience in Taiwan, "We will solve the problem of a shortage of social care workers which we have in the UK" "Not with more immigrants but with ChatGPT"

Farrukh

67,653 görüntüleme • 11 ay önce

Ketogenic diets in the ICU? The research is beginning to explore it. In a randomized controlled trial of 40 patients with sepsis, investigators tested a medically supervised ketogenic diet during critical illness. All patients in the ketogenic group achieved stable nutritional ketosis, with no serious adverse events attributed to the intervention. After day four, none of the ketogenic patients required insulin — compared to 35–60% of patients in the control group on any given day. The ketogenic group also experienced: • More ventilator-free days • More vasopressor-free days • More dialysis-free days • More ICU-free days Researchers observed signals consistent with reduced immune dysregulation and lower inflammatory signaling — a meaningful finding in a condition defined by metabolic chaos and systemic inflammation. This was a small, early-phase trial. It does not establish standard of care. But it adds to a growing body of evidence that metabolic therapy may have applications beyond chronic disease — including critical care. Check out the link below with details on how to access 150+ research summaries on metabolic health and therapy in our new Ketogenic Metabolic Therapy eBook!
2:07

Ketogenic diets in the ICU? The research is beginning to explore it. In a randomized controlled trial of 40 patients with sepsis, investigators tested a medically supervised ketogenic diet during critical illness. All patients in the ketogenic group achieved stable nutritional ketosis, with no serious adverse events attributed to the intervention. After day four, none of the ketogenic patients required insulin — compared to 35–60% of patients in the control group on any given day. The ketogenic group also experienced: • More ventilator-free days • More vasopressor-free days • More dialysis-free days • More ICU-free days Researchers observed signals consistent with reduced immune dysregulation and lower inflammatory signaling — a meaningful finding in a condition defined by metabolic chaos and systemic inflammation. This was a small, early-phase trial. It does not establish standard of care. But it adds to a growing body of evidence that metabolic therapy may have applications beyond chronic disease — including critical care. Check out the link below with details on how to access 150+ research summaries on metabolic health and therapy in our new Ketogenic Metabolic Therapy eBook!

Metabolic Health Summit

41,740 görüntüleme • 4 ay önce

The New England Journal of Medicine (NEJM) today published a peer-reviewed original paper with the results of a landmark clinical trial of our PRIMA brain-computer interface (BCI) retinal implant.
7:30

The New England Journal of Medicine (NEJM) today published a peer-reviewed original paper with the results of a landmark clinical trial of our PRIMA brain-computer interface (BCI) retinal implant.

Science Corporation

29,275 görüntüleme • 8 ay önce

An ASCO task force paper published today in ACS Journal Cancer details 3 calls-to-action for the oncology research and care communities that could expand access to clinical trials and enable patients to participate closer to home. Learn more: #OncTwitter
0:45

An ASCO task force paper published today in ACS Journal Cancer details 3 calls-to-action for the oncology research and care communities that could expand access to clinical trials and enable patients to participate closer to home. Learn more: #OncTwitter

ASCO

20,065 görüntüleme • 2 yıl önce

In patients with atrial fibrillation and a drug-eluting stent placed at least 1 year earlier, monotherapy with a non–vitamin K antagonist oral anticoagulant was noninferior to combination therapy with clopidogrel for net adverse clinical events. Full ADAPT AF-DES trial results and Research Summary:
1:29

In patients with atrial fibrillation and a drug-eluting stent placed at least 1 year earlier, monotherapy with a non–vitamin K antagonist oral anticoagulant was noninferior to combination therapy with clopidogrel for net adverse clinical events. Full ADAPT AF-DES trial results and Research Summary:

NEJM

12,252 görüntüleme • 4 ay önce

.Strand AI builds foundation models to fill in missing patient data. They predict unmeasured biological modalities from existing ones, turning sparse clinical trial datasets into complete multimodal profiles. Congrats on the launch, עודד | oded and Yue!
1:32

.Strand AI builds foundation models to fill in missing patient data. They predict unmeasured biological modalities from existing ones, turning sparse clinical trial datasets into complete multimodal profiles. Congrats on the launch, עודד | oded and Yue!

Y Combinator

12,046 görüntüleme • 4 ay önce

Blank Bio (Blank Bio) is building foundation models to power a computational toolkit for RNA therapeutics, starting with mRNA design and expanding to target ID, biomarker discovery, and more. Congrats on the launch, Jonny, Phil Fradkin & Ian Shi!
2:56

Blank Bio (Blank Bio) is building foundation models to power a computational toolkit for RNA therapeutics, starting with mRNA design and expanding to target ID, biomarker discovery, and more. Congrats on the launch, Jonny, Phil Fradkin & Ian Shi!

Y Combinator

96,728 görüntüleme • 11 ay önce

🚨NEARLY HALF OF CANCER PATIENTS TAKING IVERMECTIN + MEBENDAZOLE REPORTED CANCER DISAPPEARANCE OR TUMOR REGRESSION AFTER 6 MONTHS 84.4% EXPERIENCED CLINICAL BENEFIT 32.8% REPORTED NO EVIDENCE OF DISEASE 15.6% REPORTED TUMOR REGRESSION 36.1% REPORTED STABLE DISEASE Our study represents the largest and most compelling clinical signal to date supporting antiparasitic therapy in cancer.
1:34

🚨NEARLY HALF OF CANCER PATIENTS TAKING IVERMECTIN + MEBENDAZOLE REPORTED CANCER DISAPPEARANCE OR TUMOR REGRESSION AFTER 6 MONTHS 84.4% EXPERIENCED CLINICAL BENEFIT 32.8% REPORTED NO EVIDENCE OF DISEASE 15.6% REPORTED TUMOR REGRESSION 36.1% REPORTED STABLE DISEASE Our study represents the largest and most compelling clinical signal to date supporting antiparasitic therapy in cancer.

Joe Tippens

56,040 görüntüleme • 3 ay önce

🚨NEARLY HALF OF CANCER PATIENTS TAKING IVERMECTIN + MEBENDAZOLE REPORTED CANCER DISAPPEARANCE OR TUMOR REGRESSION AFTER 6 MONTHS 84.4% EXPERIENCED CLINICAL BENEFIT 32.8% REPORTED NO EVIDENCE OF DISEASE 15.6% REPORTED TUMOR REGRESSION 36.1% REPORTED STABLE DISEASE Our study represents the largest and most compelling clinical signal to date supporting antiparasitic therapy in cancer. McCullough Foundation The Wellness Company Peter A. McCullough, MD, MPH® Harvey Risch Kelly Victory MD James Thorp MD Dr. Drew Peter Gillooly Foster Coulson
1:34

🚨NEARLY HALF OF CANCER PATIENTS TAKING IVERMECTIN + MEBENDAZOLE REPORTED CANCER DISAPPEARANCE OR TUMOR REGRESSION AFTER 6 MONTHS 84.4% EXPERIENCED CLINICAL BENEFIT 32.8% REPORTED NO EVIDENCE OF DISEASE 15.6% REPORTED TUMOR REGRESSION 36.1% REPORTED STABLE DISEASE Our study represents the largest and most compelling clinical signal to date supporting antiparasitic therapy in cancer. McCullough Foundation The Wellness Company Peter A. McCullough, MD, MPH® Harvey Risch Kelly Victory MD James Thorp MD Dr. Drew Peter Gillooly Foster Coulson

Nicolas Hulscher, MPH

761,783 görüntüleme • 3 ay önce

In the phase 3 OCEANIC-STROKE trial involving patients with noncardioembolic ischemic stroke or high-risk TIA, asundexian added to antiplatelet therapy led to a lower risk of ischemic stroke without increasing major bleeding. Full trial results and Research Summary:
1:06

In the phase 3 OCEANIC-STROKE trial involving patients with noncardioembolic ischemic stroke or high-risk TIA, asundexian added to antiplatelet therapy led to a lower risk of ischemic stroke without increasing major bleeding. Full trial results and Research Summary:

NEJM

12,312 görüntüleme • 2 ay önce

On the ground alongside CA Fire Foundation, we got to speak with the brave firefighters and the local community in the frontlines of the recovery efforts. Together we can make a real impact. Join us in contributing to CA Fire Foundation's mission—tap our link in bio to donate today.
1:03

On the ground alongside CA Fire Foundation, we got to speak with the brave firefighters and the local community in the frontlines of the recovery efforts. Together we can make a real impact. Join us in contributing to CA Fire Foundation's mission—tap our link in bio to donate today.

Uber Eats

20,117 görüntüleme • 1 yıl önce

When nature has a problem to solve, it makes a protein. Now, with the help of AI, what we used to have to do with electronics or optics we can increasingly do through biology. Starting with the world’s most sensitive optogenetic channels. Paper linked below ⬇️
3:18

When nature has a problem to solve, it makes a protein. Now, with the help of AI, what we used to have to do with electronics or optics we can increasingly do through biology. Starting with the world’s most sensitive optogenetic channels. Paper linked below ⬇️

Max Hodak

109,421 görüntüleme • 9 ay önce

Cancer reportedly DISAPPEARED or REGRESSED in nearly HALF of patients using ivermectin + mebendazole in the LARGEST real-world study to date. After just 6 months, 84.4% of cancer patients reported CLINICAL BENEFIT with these anti-parasitics. Clinical trials are now NECESSARY.
1:12

Cancer reportedly DISAPPEARED or REGRESSED in nearly HALF of patients using ivermectin + mebendazole in the LARGEST real-world study to date. After just 6 months, 84.4% of cancer patients reported CLINICAL BENEFIT with these anti-parasitics. Clinical trials are now NECESSARY.

Nicolas Hulscher, MPH

100,406 görüntüleme • 2 ay önce

'in the midst of so much bad news recently, i have some good news to share! so recently we heard a REALLY good song, which will be on our new album~ wait for it~'
0:20

'in the midst of so much bad news recently, i have some good news to share! so recently we heard a REALLY good song, which will be on our new album~ wait for it~'

🍒 XIAOJUN WAVES

92,424 görüntüleme • 3 ay önce

Today we’re releasing V-JEPA, a method for teaching machines to understand and model the physical world by watching videos. This work is another important step towards Yann LeCun’s outlined vision of AI models that use a learned understanding of the world to plan, reason and accomplish complex tasks. Details ➡️ We're releasing a collection of V-JEPA vision models trained with a feature prediction objective using self-supervised learning. The models are able to understand and predict what is going on in a video, even with limited information. It learns by predicting missing or obscured parts of a video in its internal feature space. Unlike generative approaches that fill in missing pixels, this flexible approach enables up to 6x improvements in training and sample efficiency. The models were pre-trained on entirely unlabeled data, and a small amount of labeled data can be used to train a task-specific prediction head on top after pre-training. Our results show that, using a frozen backbone, our top V-JEPA models achieve 82.0% on Kinetics-400, 72.2% on Something-Something-v2 and 77.9% on ImageNet1K — competitive with or exceeding previous leading video models. We believe that this work is an important milestone on the path to advancing machine intelligence.
1:07

Today we’re releasing V-JEPA, a method for teaching machines to understand and model the physical world by watching videos. This work is another important step towards Yann LeCun’s outlined vision of AI models that use a learned understanding of the world to plan, reason and accomplish complex tasks. Details ➡️ We're releasing a collection of V-JEPA vision models trained with a feature prediction objective using self-supervised learning. The models are able to understand and predict what is going on in a video, even with limited information. It learns by predicting missing or obscured parts of a video in its internal feature space. Unlike generative approaches that fill in missing pixels, this flexible approach enables up to 6x improvements in training and sample efficiency. The models were pre-trained on entirely unlabeled data, and a small amount of labeled data can be used to train a task-specific prediction head on top after pre-training. Our results show that, using a frozen backbone, our top V-JEPA models achieve 82.0% on Kinetics-400, 72.2% on Something-Something-v2 and 77.9% on ImageNet1K — competitive with or exceeding previous leading video models. We believe that this work is an important milestone on the path to advancing machine intelligence.

AI at Meta

703,647 görüntüleme • 2 yıl önce

We’re excited to announce positive results from our BroADen Phase 1b clinical trial of KT-621, our investigational, first-in-class, oral STAT6 degrader, in patients with moderate to severe atopic dermatitis. The data provide a powerful validation of our industry-leading STAT6 degrader program and help accelerate our goal to deliver novel oral medicines to millions of patients around the world. Our deepest thanks to the patients, investigators, and the incredible Kymera team whose dedication made this significant milestone possible. Read more about the promising KT-621 data in our press release and join our live video webcast at 8:00AM ET today: #RevolutionizingImmunology
2:02

We’re excited to announce positive results from our BroADen Phase 1b clinical trial of KT-621, our investigational, first-in-class, oral STAT6 degrader, in patients with moderate to severe atopic dermatitis. The data provide a powerful validation of our industry-leading STAT6 degrader program and help accelerate our goal to deliver novel oral medicines to millions of patients around the world. Our deepest thanks to the patients, investigators, and the incredible Kymera team whose dedication made this significant milestone possible. Read more about the promising KT-621 data in our press release and join our live video webcast at 8:00AM ET today: #RevolutionizingImmunology

Kymera Therapeutics

15,338 görüntüleme • 7 ay önce

An experimental gene therapy from UniQuire reduced disease progression in Huntington's patients by 75% over 36 months in a clinical trial, marking a significant milestone for the rare inherited brain disorder that has no FDA-approved treatments
1:09

An experimental gene therapy from UniQuire reduced disease progression in Huntington's patients by 75% over 36 months in a clinical trial, marking a significant milestone for the rare inherited brain disorder that has no FDA-approved treatments

Reuters

53,077 görüntüleme • 9 ay önce

We are excited to be working on a new research study which is aiming to create a lateral flow test (LFT) to determine whether a patient is suffering a stroke. We are working alongside the University of Birmingham and University Hospitals Birmingham on the Ghost study, which will see us obtain saliva from patients who are demonstrating stroke symptoms, to help create an LFT which in turn will help to speed up access to brain-saving treatment and saving more patients. You can read more here -
1:51

We are excited to be working on a new research study which is aiming to create a lateral flow test (LFT) to determine whether a patient is suffering a stroke. We are working alongside the University of Birmingham and University Hospitals Birmingham on the Ghost study, which will see us obtain saliva from patients who are demonstrating stroke symptoms, to help create an LFT which in turn will help to speed up access to brain-saving treatment and saving more patients. You can read more here -

West Midlands Ambulance Service #HelpUsHelpYou

20,526 görüntüleme • 1 yıl önce